PAR PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PAR PHARM, and when can generic versions of PAR PHARM drugs launch?
PAR PHARM has one hundred and fifty-three approved drugs.
There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and ninety supplementary protection certificates in fifteen countries.
Summary for PAR PHARM
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 98 |
| Ingredients: | 96 |
| NDAs: | 153 |
| Patent Litigation for PAR PHARM: | See patent lawsuits for PAR PHARM |
| PTAB Cases with PAR PHARM as petitioner: | See PTAB cases with PAR PHARM as petitioner |
Drugs and US Patents for PAR PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm | OXYMORPHONE HYDROCHLORIDE | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200792-005 | Oct 24, 2014 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm Inc | AMBRISENTAN | ambrisentan | TABLET;ORAL | 209509-002 | Apr 10, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Pharm | TIOPRONIN | tiopronin | TABLET, DELAYED RELEASE;ORAL | 217219-002 | Feb 24, 2023 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm | URSODIOL | ursodiol | TABLET;ORAL | 202540-002 | Feb 14, 2013 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Pharm | QUETIAPINE FUMARATE | quetiapine fumarate | TABLET, EXTENDED RELEASE;ORAL | 090482-004 | May 9, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm | MECLOFENAMATE SODIUM | meclofenamate sodium | CAPSULE;ORAL | 072077-001 | Mar 10, 1988 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PAR PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | 4,724,231 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for PAR PHARM Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2006240490 | ⤷ Try a Trial |
| Japan | 2008538560 | ⤷ Try a Trial |
| European Patent Office | 1948613 | ⤷ Try a Trial |
| South Korea | 20080000660 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2006115626 | ⤷ Try a Trial |
| Canada | 2605413 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PAR PHARM Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0454511 | 99C0009 | Belgium | ⤷ Try a Trial | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
| 2203431 | CA 2015 00014 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115 |
| 2435024 | 21C1020 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210 |
| 0480717 | 98C0022 | France | ⤷ Try a Trial | PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825 |
| 0503785 | C300486 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216 |
| 2236132 | 122015000006 | Germany | ⤷ Try a Trial | PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
